4
Changes in Ownership
Beam Therapeutics Inc. Filed Acc 0000899243-21-016869
CEO sold 25,000 shares at an average $70.49 ($1,762,216)
- CEO acquired 6,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Evans John M. CEO | 2021-04-21 | Sale | −1,463 | $67.90 | $99,338 | 1,038,966 | D |
| Evans John M. CEO | 2021-04-21 | Sale | −5,079 | $69.02 | $350,553 | 1,033,887 | D |
| Evans John M. CEO | 2021-04-21 | Sale | −5,595 | $70.23 | $392,937 | 1,028,292 | D |
| Evans John M. CEO | 2021-04-21 | Sale | −9,869 | $71.38 | $704,449 | 1,018,423 | D |
| Evans John M. CEO | 2021-04-21 | Sale | −2,994 | $71.79 | $214,939 | 1,015,429 | D |
| Evans John M. CEO | 2021-04-23 | Option exercise | +6,000 | $1.03 | $6,180 | 1,021,429 | D |
| Derivatives | |||||||
| Evans John M. CEO | 2021-04-23 | Option exercise · Stock Option (Right to Buy) | −6,000 | 396,345 | D | ||
| Open-market sales · 25,000 sh · avg $70.49 · $1,762,216 | |||||||
Loading xslF345X03/doc4.xml…